Charles River Laboratories Profit Margin 2006-2018 | CRL

Current and historical gross margin, operating margin and net profit margin for Charles River Laboratories (CRL) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Charles River Laboratories net profit margin as of December 31, 2018 is 9.99%.
Charles River Laboratories Annual Profit Margins
Charles River Laboratories Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical Services $6.737B $2.266B
Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Their dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. At Charles River, they are passionate about their role in improving the quality of people's lives. Their mission, their excellent science and strong sense of purpose guide in all that they do, and they approach each day with the knowledge that their work helps to improve the health and well-being of many across the globe. Charles River Laboratories International, Inc. service areas are Basic research, discovery, safety and efficacy, clinical support and manufacturing.
Stock Name Country Market Cap PE Ratio
ICON (ICLR) Ireland $7.792B 24.42
PRA Health Sciences (PRAH) United States $7.283B 29.73
NovoCure (NVCR) Jersey $4.888B 0.00
Premier (PINC) United States $4.816B 16.33
HealthEquity (HQY) United States $4.728B 92.42
Teladoc (TDOC) United States $4.668B 0.00
AMN Healthcare Services Inc (AMN) United States $3.046B 19.76
BioTelemetry (BEAT) United States $2.531B 44.71
Medpace Holdings (MEDP) United States $2.434B 30.11
Intrexon (XON) United States $1.040B 0.00
Natera (NTRA) United States $1.000B 0.00
CareDx (CDNA) United States $0.933B 0.00
Healthways (TVTY) United States $0.846B 10.41
China Cord Blood (CO) China $0.817B 22.40
Apollo Medical Holdings (AMEH) United States $0.651B 0.00
Civitas Solutions (CIVI) United States $0.643B 10.61
Surgery Partners (SGRY) United States $0.641B 0.00
Establishment Labs Holdings (ESTA) $0.516B 0.00
OncoCyte (OCX) United States $0.198B 0.00
Imprimis Pharmaceuticals (HROW) United States $0.143B 0.00
Interpace Diagnostics (IDXG) United States $0.027B 0.00
OpGen (OPGN) United States $0.012B 0.00
Cancer Genetics (CGIX) United States $0.007B 0.00
FORM Holdings (XSPA) United States $0.006B 0.00
Biocept (BIOC) United States $0.002B 0.00